VIDEO: Indirect comparison yields similar risk, benefit profiles among UC treatment

VIDEO: Indirect comparison yields similar risk, benefit profiles among UC treatment

LAS VEGAS – Matching-adjusted indirect comparisons found a positive benefit-risk profile for ozanimod vs. adalimumab and a comparable profile for ozanimod vs. vedolizumab.“This is not doing head-to-head trials. This is using a methodology which allows you to look at like patient populations and comments on the benefit-risk profile,” Marla Dubinsky, MD, of the Icahn School of Medicine, said in a video exclusive with Healio Gastroenterology. “It was great to see how we’re going to be thinking as new targets come. … We’ll keep doing these modifiedRead More

Share on facebook
Share on twitter
Share on linkedin